Guillain-Barre syndrome after vaccination in United States. A report from the CDC/FDA Vaccine Adverse Event Reporting System

Vaccine

Volumn 25, Issue 29, 2007, Pages 5253-5255

  Souayah, Nizar ^a   Nasar, Abu ^b   Suri, M Fareed K ^a   Qureshi, Adnan I ^a  

^a Zeenat Qureshi Stroke Research Center   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Adverse event; Guillain Barre syndrome; Hepatitis vaccine; Influenza vaccine; Vaccination

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HEPATITIS VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE; TYPHOID VACCINE; YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DEATH; DISABILITY; DRUG EFFECT; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; VACCINATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; GUILLAIN-BARRE SYNDROME; HUMANS; INCIDENCE; INFLUENZA VACCINES; UNITED STATES; VACCINATION;

EID: 34250810715     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.053     Document Type: Article

References (12)

1. Fenichel G.M. Assessment: neurologic risk of immunization. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 52 8 (1999) 1546-1552
2. Patja A., Paunio M., Kinnunen E., Junttila O., Hovi T., and Peltola H. Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination. J Pediatr 138 2 (2001) 250-254
3. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 339 25 (1998) 1797-1802
4. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 110 2 (1979) 105-123
5. Safranek T.J., Lawrence D.N., Kurland L.T., Culver D.H., Wiederholt W.C., Hayner N.S., et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 133 9 (1991) 940-951
6. Hughes R.A., Charlton J., Latinovic R., and Gulliford M.C. No association between immunization and Guillain-Barre syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 166 12 (2006) 1301-1304
7. Haber P., DeStefano F., Angulo F.J., Iskander J., Shadomy S.V., Weintraub E., et al. Guillain-Barre syndrome following influenza vaccination. JAMA 292 20 (2004) 2478-2481
8. Sejvar J.J., Labutta R.J., Chapman L.E., Grabenstein J.D., Iskander J., and Lane J.M. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 294 21 (2005) 2744-2750
9. Hughes R.A., and Cornblath D.R. Guillain-Barre syndrome. Lancet 366 9497 (2005) 1653-1666
10. Duchini A., Hendry R.M., Redfield D.C., and Pockros P.J. Influenza infection in patients before and after liver transplantation. Liver Transpl 6 5 (2000) 531-542
11. Magnani G., Falchetti E., Pollini G., Reggiani L.B., Grigioni F., Coccolo F., et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 24 5 (2005) 588-592
12. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 9492 (2005) 1175-1181